NCT02335879已完成3 期
Phase III Clinical Study of Domestic Recombinant Human Follitropin for Injection to Treat WHO Class II Anovulation
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 534
- 主要终点
- The efficiency reached mature follicle (the diameter of follicular ≥18mm by type-B ultrasonic) within the start period on the day of HCG day.
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of Domestic Recombinant Human Follitropin (Gonal-F) for Injection for treatment of WHO Ⅱ anovulation (including polycystic ovarian syndrome [PCOS] subjects).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 21 Years 至 38 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Married infertile women at the age of 21-
- •BMI<28kg/m
- •According to the detection level of serum estradiol (E2), prolactin (PRL), progesterone (P), testosterone (T), luteinizing hormone (LH), follicle stimulating hormone (FSH), subjects were diagnosed of WHO class II anovulation or oligo-ovulation, and the above hormone level of the subject is normal or normal after treatment at the beginning of study, and FSH<10IU/L.
- •Bilateral fallopian tubes are unobstructed proved by hysterosalpingograph or laparoscopic examination within one year, no history of abortion or pelvic infection after the examination, the researcher decide whether the above examination need to repeat. If the subject had salpingoplasty under laparoscope, and the bilateral fallopian tubes are unobstructed after the surgery, there is no need to have the hysterosalpingograph. If it can not be confirmed, it must be done again to prove that the bilateral fallopian tubes are unobstructed.
- •Vaginal B-ultrasound examination shows that there is no ovarian pathological tumor, no hysteromyoma or hysteromyoma<4cm, and does not affect the endometrial function.
- •Two examinations of spouse semen are normal within six months, or comply with the IUI standard.
- •No history of drug abuse.
- •Voluntarily sign the informed consent form and agree with medication and accepting evaluation according to the requirements of the research protocol.
排除标准
- •The subject use gonadotropin therapy within the past three months (regardless the result of treatment).
- •The uterine factors affect pregnancy and other tumors.
- •Pregnancy contraindication, such as genetic diseases, mental diseases, drug abuse, sexually transmitted diseases, severe heart disease and hepatic and kidney function insufficiency.
- •Obscure vaginal bleeding.
- •Subjects are allergic to the application of FSH/HMG and HCG in the past.
- •Other conditions that the researchers think they are not suitable for the clinical trials.
结局指标
主要结局
The efficiency reached mature follicle (the diameter of follicular ≥18mm by type-B ultrasonic) within the start period on the day of HCG day.
时间窗: participants will be followed within the HCG day, an expected average of 14±2 days
次要结局
未报告次要终点
研究者
相似试验
Unknown
3 期
Clinical Study of Recombinant Human Follitropin for Injection Assisted in COH Assisted IVF-ETOvarian Hyperstimulation SyndromeNCT03071172Changchun GeneScience Pharmaceutical Co., Ltd.252
已完成
3 期
Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia AHemophilia ANCT04845399Zhengzhou Gensciences Inc101
已完成
3 期
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE AttacksHereditary AngioedemaNCT01188564Pharming Technologies B.V.75
已完成
1 期
A Phase Ib/III Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in Patients With Small Cell Lung Cancer Who Have Failed First-line or Above ChemotherapiesSmall Cell Lung CarcinomaNCT04672928Innovent Biologics (Suzhou) Co. Ltd.20
终止
3 期
A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary FibrosisNCT04552899Hoffmann-La Roche665